title: Hepatitis C: a challenge for the generalist.
abstract: Most cases of hepatitis C become chronic, and although many of those remain silent for decades, some eventually progress to cirrhosis or other complications. Since almost 2% of the U.S. population is already infected, clinicians are likely to encounter growing numbers of patients with progressive disease. Treatment has been modified; ribavirin can now be added to interferon therapy.
authors.affiliation: Connecticut Emerging Infections Program, Yale University, New Haven, USA.
authors.forename: G
authors.initials: G
authors.lastname: Catalina
authors.forename: V
authors.initials: V
authors.lastname: Navarro
mesh_terms: D000465:Algorithms; D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D003663:Decision Trees; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy* / Q000635:transmission; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D011320:Primary Health Care / Q000379:methods*; D011322:Primary Prevention / Q000379:methods; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D012720:Severity of Illness Index; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons